Drug intelligence / Profile preview

Shuertong

Development stage: Unknown
Lead developer: Kunming Bondir Pharmaceutical Research
Administration: Oral

Overview

**Shuertong** is an investigational oral traditional Chinese medicine analgesic supplied as a dispersible tablet. It is a botanical mixture prepared from purified extracts of *Corydalis decumbens* rhizome and tree peony bark, developed by Kunming Bondir Pharmaceutical Research for pain associated with the traditional Chinese medicine pattern of qi stagnation and blood stasis. Its molecular targets and pharmacologic mechanism have not been publicly established. A completed Phase 1 single-ascending-dose safety study in healthy volunteers was registered as CTR20131965; a Chinese patent describes the product as an analgesic botanical medicine. ([pharnexcloud.com](https://www.pharnexcloud.com/data/lcsy_f0feb92ccfc89fdcaec5db2136e6f672.html))

Other names: Shu'ertong Dispersible TabletsShuertong Dispersible Tablets舒尔痛分散片

Beyond the preview

Go deeper on Shuertong.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shuertong.

Explore the full profile